Integration of morphological and immunophenotypic data is critical in achieving diagnosis accuracy and minimising interobserver interpretative discrepancies. The aim of this work was to compare the immunophenotype and the morphology of chronic lymphocytic leukaemia and mantle cell lymphoma, to help in the differential diagnosis of CD5 positive monoclonal B cells. Frozen/thawed samples from 91 patients were analysed retrospectively. Fresh samples from 17 mixed/atypical CLL and 13 MCL were tested to corroborate the results. Markers were analysed as percentage (%) of positive B lymphocyte subpopulation, and in terms of median fluorescence intensity (MFI). Matutes's CLL score clearly allowed distinguishing between classical CLL on the one hand, and atypical CLL and MCL on the other hand. The percentage of CD54-positive cells and the median fluorescence intensity of CD20 and CD54 were the only parameters which were significantly higher in MCL than in atypical CLL (P Ͻ 0.05), allowing an immunological distinction between these two entities. Nevertheless, due to a quenching problem when using CD20 and CD54 together, and because CD18 showed a statistically different expression between classical and atypical CLL, the combination of CD18/CD54 has been preferred and showed a different pattern in the three entities. Immunophenotyping could be helpful in the differential diagnosis of CD5-positive B cell chronic lymphoproliferative disorders with atypical features that do not fit exactly into any of the morphologic proposed groups. Leukemia (2001) 15, 1458-1465.
Introduction
The conjunction of clinical features, cell morphology and immunological features allows an accurate diagnosis in most cases of B cell chronic lymphoproliferative disorders. However, the diagnosis remains uncertain in a small percentage of cases. Morphologic and immunophenotypic heterogeneity of chronic lymphocytic leukaemia (CLL) has long been recognized. In addition, its clinical behaviour, even within a clinical stage, is highly variable. By morphology, CLL was subdivided into typical (CLL, monomorphic) and atypical (CLL, mixed cell types) entities in the FAB classification proposal. 1 'Classical' CLL with its small lymphocytes with clumped chromatin is morphologically easy to diagnose. Moreover, the immunophenotype of classical CLL is mostly quite clear: Matutes et al 2 a few years ago, described a scoring system based on five markers with a high differential diagnosis power. This scoring system was tested in our institution and in a multicentric study, with concordant results. In contrast, atypical CLL, with its heterogeneous morphology, is sometimes more difficult to diagnose. Likewise, its immunophenotype is not characteristic. CLL and mantle cell lymphoma (MCL) are both characterized by a proliferation of CD5-positive neoplas- tic B cells. An accurate differential diagnosis between these two malignancies is important for guiding treatment options. Integration of morphological and immunophenotypic data is critical in achieving diagnosis accuracy and minimising interobserver interpretative discrepancies. Therefore, the aim of this work was to compare the results of a retrospective extensive immunophenotyping of CLL and MCL B cells, to help in the differential diagnosis of CD5-positive monoclonal B cells.
Materials and methods

Samples
Samples from 77 patients suffering from CLL and from 14 patients suffering from MCL were studied. Table 1 shows the characteristics of the patients. There was no difference in sex ratio and age between the groups. The majority of CLL patients were at stage A (Binet stratification), whereas nearly all MCL patients were at stage 4 (Ann Arbor stratification). All MCL patients were treated immediately after diagnosis, but only 55% of the CLL patients were treated after a mean time of 26 months. As already described, the prognosis was worse in the MCL group (only 57% patients were still alive at last observation), than in the CLL group (84% alive), as illustrated in the overall survival curve (Figure 1a) . Peripheral blood samples were studied for CLL patients. For MCL, depending on the availability of the specimens, different samples were studied: lymph node (n = 4), bone marrow (n = 6) or peripheral blood (n = 4). Diagnosis was based on morphology according to the FAB classification 1 and to the Working Formulation 3 criteria. Examination of the slides was performed by two persons and blindly reviewed by an independent observer. When possible (n = 13/14), MCL diagnosis was cor- Table 1 Characteristics of the patients of the CLL group (n = 77) and the MCL group (n = 14)
CLL MCL
Sex ratio (M/F) roborated by cytogenetic (translocation t(11;14)(q13;q32)) or molecular (BCL1 rearrangement) studies.
Among CLL patients, 67 were morphologically and immunologically 2 diagnosed as 'classical' CLL and 10 as mixed or atypical CLL. No statistical difference was observed between either CLL group in term of sex ratio (classical CLL: 1.48, atypical CLL: 2.3), age (classical CLL: 64.8 years (36-86), atypical CLL: 56.9 years (25-79)), stage (classical CLL: 87% in stage A, atypical CLL: 70%; no patient was at stage C), percentage of treated patients (classical CLL: 52%, atypical CLL: 70%), but the patients in the atypical CLL group were treated sooner (mean time between diagnosis and treatment: 30.9 months in the classical CLL group, 9.3 months in the atypical one, P = 0.03). The overall survival was not statistically different, as illustrated in Figure 1b . In none of the CLL cases was a t (11;14) or its molecular equivalent observed.
Peripheral blood was collected on EDTA. Bone marrow aspirates were collected in a syringe containing 5% heparin plus 25% human albumin solution (concentration 4 g/dl, Belgian Red Cross, Brussels, Belgium), and filtered through a fine needle to avoid clotting in the cell suspension. Lymph nodes were collected in sterile-buffered saline solution, immediately dilacerated and resuspended in minimal essential medium (MEM; Gibco, Life Technologies, Rockville, MD, USA) containing 2.5% Hepes (Gibco) and 10% fetal calf serum (Biosys, Compiègne, France). After erythrocyte NH4Cl lysis and washing, bone marrow and peripheral blood cells were resuspended in MEM supplemented with 2.5% Hepes and 10% fetal calf serum. All samples were cryopreserved in Leukemia 10% dimethylsulfoxide (DMSO, Merck, Darmstadt, Germany) final concentration. Vials were first placed at −80°C for 24 hours and stored thereafter in liquid nitrogen until the day of analysis. Cells were thawed rapidly by immersion in a waterbath at 37°C, diluted in MEM and processed rapidly. Finally, 30 new samples (17 mixed/atypical CLL and 13 MCL) were studied to corroborate the results obtained on frozen/thawed cells.
Cell staining
To restrict the evaluation to the B cell compartment, CD19-Cy5 was chosen as the gating tool for each marker. The following FITC-/PE-(fluorescein isothiocyanate/ phycoerythrin) monoclonal antibody combinations were tested: CD5/CD23, FMC7/CD19, CD44/CD24, CD95/CD79b, CD20/ − , CD54/CD40, CD18/CD11a, /IgD, /IgD, CD22/CD10, CD103/CD11c, CD43/ − , CD18/CD54. CD5, CD22, CD11c were provided by IQP, CD20 and CD23 by Becton Dickinson (Erembodegem, Belgium), CD19-Cy5 and CD43 by Pharmingen (Erembodegem, Belgium), kappa and lambda by Dako, IgD by SBA, CD10 by Coulter (Brea, CA, USA), CD11a, CD18, CD19-PE, CD24, CD40, CD44, CD54, CD79b, CD95, CD103 and FMC7 by Immunotech (Brea, CA, USA). Optimal dilution was determined previously, ie at saturating concentration. Each monoclonal reagent combination was added to 100 l peripheral blood, bone marrow or lymph node cell suspension. Cells and monoclonal antibodies mixtures were gently vortexed and incubated at room temperature for 30 min. Samples were subsequently washed twice in saline solution (PBS; Gibco) and resuspended in 300 l PBS for analysis.
Flow cytometry analysis
Data were acquired using a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) flow cytometer. Instrument set up was performed weekly using Quality Control windows beads (Flow Cytometry Standards Corporation, San Juan, PR). Forward scatter and side scatter measurements were made with linear amplification, whereas fluorescence measurements were made with logarithmic amplifiers. Flow cytometric two-parameter dot plots and quadrant statistics were generated by CellQuest software (Becton Dickinson Immunocytometry Systems). Analysis was performed after manual gating around the lymphocyte population on a forward scatter vs side scatter dot plot. A second gate was then put on a CD19-positive subpopulation on a CD19 vs side scatter dot plot, to target the B lymphocyte population. A minimum of 2000 CD19-positive gated events was acquired for each sample. Results were expressed as percentage of positive B cells. Immunophenotype panels are usually devised for the detection of the frequency of abnormal cell populations. The most highly discriminant information is, however, not contained in percentage frequency values of cell populations, but rather in total antibody binding, antibody binding ratios, and relative antibody surface density parameters. 4 Therefore, fluorescence intensity was considered independently and expressed as the median channel of fluorescence intensity (median fluorescence intensity, MFI). The MFI values were related to channels on a linear scale of 0-1023. In routine diagnostic procedures, a shift of 50 channels is considered as significant. 5 When separation between nega-tive and positive populations is quite clear, the determination of fluorescence intensity on the positive population can be unambiguously resolved (as for CD11a, CD18, CD20, CD22, CD24, CD40, CD44, CD54, CD79b, /, IgD). However, the problem is particularly difficult when quantifying the expression of antigens that exhibit a continuous staining pattern ranging from negative to positive, 6 as for CD11c and CD43. One approach to quantifying populations with nondiscrete fluorescence signals is to report shifts in the MFI of the whole populations of interest.
7 These values must be carefully interpreted: a direct comparison of values from laboratory to laboratory would be invalid; nevertheless, the relative interpretation of MFI values obtained in one pathological entity compared to those obtained in the same conditions in another disease would be the most useful parameter for the differential diagnosis of B cell chronic lymphoproliferative disorders. A marker was considered as 'dim' if its MFI was below that obtained on 20 healthy controls tested in the same conditions, and as 'bright' if its MFI was equal to or above that obtained on normal subjects.
Statistical analysis
Data were expressed as median values and interquartile range. Comparisons between groups were performed using Mann-Whitney rank-sum test, and the significance level was set at 5%. Nevertheless, these data have to be interpreted with caution because of the relatively low number of MCL and atypical CLL. Increasing the number of cases would maybe reveal more statistical differences.
Results
Seventy-seven frozen/thawed CLL and 14 MCL samples were retrospectively studied. In each case, a monoclonal B cell population, based on immunoglobulin light chain restriction, was isolated. CLL samples were morphologically and immunologically classified as 'classical' (n = 67) or 'mixed/atypical' (n = 10). For the immunological classification, the Matutes CLL score was used. 2 This score is based on five markers (SmIg, CD5, CD23, FMC7, membrane CD22; Table 2 ) and allows the discrimination between CLL and all other B cell disorders. Results are presented in Table 3 . All classical CLL had a Matutes's CLL score of four or five. The most sensitive marker was CD5 (positive in all cases but one). CD23-positive B lymphocytes were above 30% in 63 cases of Table 2 Matutes's CLL scoring system based on the presence or absence of CD5, CD23 and FMC7 and on the level of expression of CD22 and the light chain of the surface monoclonal immunoglobulin 67, whereas FMC7-positive B lymphocytes were below 30% in 62. CD22 and / expression were bright in six cases each. Matutes's CLL score was decreased in all mixed/atypical samples compared to the classical CLL ones, because of the the absence of CD5 expression in one case, the presence of FMC7 in four cases, the high expression of CD22 in all cases, and of immunoglobulin light chain in seven cases, and the absence of CD23 in six cases. For this last marker, the absence of expression was already noted at diagnosis on freshly analysed samples. Indeed, we demonstrated that in some cases, CD23 expression could be decreased or lost after cryopreservation. 8 Matutes's CLL score was always below four in MCL samples, because of the absence of CD23 expression (already noted on freshly analysed samples, see above) in all cases, the presence of FMC7 in 12 cases, the high expression of CD22 in 12 cases and of the immunoglobulin light chain in 10 cases. The percentage of cases in which CD23 was considered as positive, was statistically different between classical CLL and atypical CLL (P Ͻ 0.0001), between classical CLL and MCL (P Ͻ 0.0001), and between atypical CLL and MCL (P = 0.01). The same was observed for the number of cases in which FMC7 was considered as negative (P = 0.01 between classical and atypical CLL, P Ͻ 0.0001 between classical CLL and MCL, P = 0.02 between atypical CLL and MCL). The proportion of classical CLL which dimly expressed CD22 or / was statistically different from the proportion of atypical CLL (P Ͻ 0.0001 for both markers) or MCL (P Ͻ 0.0001 for both markers). No difference was observed between atypical CLL and MCL for these two last markers. Table 4 shows the results of the extensive immunophenotype of classical CLL, mixed/atypical CLL and MCL retrospectively obtained in frozen/thawed samples. Results are expressed in terms of percentage (Table 4A ) and MFI (Table  4B) 
Comparison between classical CLL and mixed/atypical CLL samples
The percentage of CD11a and CD18 was statistically decreased in classical CLL (P = 0.0003 and 0.0006, respectively), whereas the percentage of CD43-positive B cells was statistically higher (P Ͻ 0.0001), compared to mixed/atypical cases. CD11a (P = 0.05), CD18 (P = 0.01), CD20 (P = 0.0002), CD22 (P Ͻ 0.0001), CD24 (P = 0.02), CD79b (P Ͻ 0.0001) and immunoglobulin light chain (P = 0.0005) MFI was statistically weaker, but CD43 MFI (P Ͻ 0.0001) was higher in classical CLL than in mixed/atypical CLL. The other markers did not show any statistical difference in terms of percentage of positive B cells, or in terms of MFI (P Ͼ 0.05).
Influence of sample origin on MCL phenotype
Depending on the availability of the specimens, samples from variable origins were studied for MCL patients. In most cases, a direct comparison of the immunophenotype obtained on lymph node and bone marrow/peripheral blood in the same patient was not possible: either the lymphoma was not disseminated in the blood and a lymph node was surgically taken and studied, or the bone marrow and the peripheral blood 
Comparison between classical CLL and MCL samples
The percentage of CD11c (P = 0.02) and CD43 (P Ͻ 0.0001)-positive B cells was statistically decreased in MCL samples compared to the classical CLL ones, whereas the percentage of CD18 (P = 0.002) and CD54 (P = 0.0009) was statistically increased. The MFI values of CD11c (P = 0.023) and CD43 (P Ͻ 0.0001) were statistically weaker in MCL, but the fluorescence intensity of CD20 (P Ͻ 0.0001), CD22 (P Ͻ 0.0001), CD24 (P = 0.002), CD54 (P Ͼ 0.0001), CD79b (P Ͻ 0.0001) and immunoglobulin light chain (P Ͻ 0.0001) was statistically higher in MCL compared to classical CLL. No other marker showed any statistical difference in terms of percentage of positive B cells, in terms of MFI (P Ͼ 0.05).
Comparison between mixed/atypical CLL and MCL samples
The The percentage of CD54-positive cells and the median fluorescence intensity of CD20 and CD54 were the only parameters which were significantly higher in MCL than in atypical CLL (P Ͻ 0.05), allowing an immunological distinction between these two entities. Nevertheless, due to a quenching problem when using CD20 and CD54 together, and because CD18 showed a statistically different expression between classical and atypical CLL, the combination of CD18/CD54 has been preferred and showed a different pattern of expression in the three entities (Figure 3) .
Correlation between immunophenotype and clinical course
Finally, in each clinical entity, a correlation between the antigen pattern and the clinical course of the patients (eg overall survival) has been searched for. Contrary to the data already published, [9] [10] [11] [12] no correlation has been found, but the number of patients was very low, and this has to be controlled in a larger number of patients. In this study, the immunophenotype was especially useful for differential diagnosis. The wellknown bad prognosis of MCL compared to CLL is illustrated in Figure 1a .
Discussion
The validity of subdividing CLL into a typical and an atypical entity as proposed by the FAB group 1 is now supported by several additional findings. In comparison with typical CLL, atypical CLL frequently expresses an aberrant immunophenotype and chromosomal abnormalities, especially trisomy 12, are more frequent in atypical CLL. 13 Moreover, atypical CLL is clinically more aggressive. The Matutes's CLL score allows 
Data are presented as median (and interquartile range) of percentage of each marker on B lymphocyte subpopulation. CD40 and CD44 were expressed on all B cells in the three groups. *P Ͻ 0.05 between classical CLL and mixed/atypical CLL, **P Ͻ 0.05 between classical CLL and MCL, ***P Ͻ 0.05 between mixed/atypical CLL and MCL. The exact P value results are detailed in the text.
Table 4B
Phenotype obtained in 67 classical CLL, 10 mixed/atypical CLL and 14 MCL frozen/thawed samples: median fluorescence intensity
the identification of a homogeneous subgroup of classical CLL, that differs from atypical/mixed CLL for the five markers' expression (CD5, CD23, FMC7, CD22 and immunoglobulin light chain), but also for CD11a (% and MFI), CD18 (% and MFI), CD20 (MFI), CD24 (MFI), CD43 (% and MFI) and CD79b (MFI). The result of this last marker has already been noted by Moreau et al. 14 The immunophenotype is quite different in MCL compared to CLL: if both pathological cells are CD5 positive, CD23 is negative in MCL and almost always positive in CLL. However the latter marker is not always discriminant since in our mixed/atypical CLL cases, CD23 was negative in 60% of cases. Thus, the Matutes's CLL scoring system is very helpful for the differential diagnosis between classical CLL and the other B cell chronic lymphoproliferative disorders, but not for the immunological distinction between mixed/atypical CLL and MCL malignant B cells. A more extensive immunophenotype might be more adequate for the differential diagnosis between the last two pathologies, especially when peripheral blood or bone marrow aspirates are the only specimens available for analysis. Indeed, if the common circulating cells in MCL are often quite typical, in a few cases, the cytological picture is similar to that described for CLL of mixed cells type (CLL/PL). 15 The simple determination of the percentage of positive cells often did not discriminate between these pathologies. Therefore, the best way to compare the molecule expression is to consider the fluorescence intensity. Quantification using flow cytometry has rarely been reported in the literature but it has been recently proved to be effective in the differential diagnosis of non-Hodgkin's lymphomas. 16 In our experience, the results of MCL immunophenotype were not dependent upon sample origin, bone marrow, peripheral blood or lymph node. Therefore, the results obtained in all MCL samples were globally compared to those obtained in mixed/atypical CLL cells. Only CD20 and CD54 expression was found to be relevant for the distinction between both pathologies, and this was further confirmed on fresh samples. However, due to a quenching problem, these two markers could not be associated in the same monoclonal antibody combination. Therefore, CD18/CD54 combination was chosen: the dot plot of thses two markers' expression is particularly eloquent for the discrimination (Figure 3 ).
CD54 has a wide tissue distribution, being expressed on both haematopoietic and non-haematopoietic cells. 17 Several adhesion molecules, like CD54, CD11a/CD18, CD29/CD49d have been implicated in adhesion of B lymphocytes to stromal Leukemia cells: fibroblasts 18 or follicular dendritic cells. [19] [20] [21] The results obtained with CD11a and CD54 by Jacob et al 16 suggest that in low grade NHL, malignant cells remain localised because they are able to adhere to neighbouring cells. In the present work, CD54 and CD11a expression was not different between lymph node and peripheral blood and bone marrow, suggesting that, at least in this small group, disseminating cells had the same immunophenotype as tumour cells. Interestingly, we found a lower expression of CD54 in CLL samples (classical or mixed/atypical) than in MCL (whatever the sample origin). In 1997, Csanaky et al 11 also described a lower number of ICAM-1-positive cells in CLL cases compared to non-CLL ones. CD54 has been shown to be associated with tumour burden 22 or rapid doubling time 10 in B-CLL. The ␤2 integrin molecules, especially CD11a, CD11c, CD18 (CD11b was not studied in this work) showed a very high grade of range of percentages. This contrasted to the more homogeneous distribution in terms of fluorescence intensity of these markers. The expression of these molecules is decreased in CLL, 23 especially in association with a 11q deletion. 12 Due to the important variations of percentage of CD11a, CD11c and CD18-positive cells (the significance of these variations is unknown), these data have to be interpreted with caution; their level of expression would certainly be a more reproducible and useful parameter for the differential diagnosis of chronic lymphoproliferative disorders.
Indirect evidence suggests that CD20 functions as a B cell Ca 2+ channel subunit 24 and regulates cell cycle progression in Balb/c 3T3 cells. 25 In human malignant B cells of chronic lymphoproliferative disorders, its level of expression is widely variable: 'dim' in classical CLL and normal to 'bright' in mixed/atypical CLL and in low grade NHL. The low level of CD20 expression in CLL was described a long time ago, and the usefulness of CD20 evaluation in the differential diagnosis of B cell chronic lymphoproliferative disorders was recently confirmed, 26, 27 but D'Arena et al 28 could not demonstrate quantitative differences between atypical CLL and MCL. The significance of CD20 expression variability in malignant lymphoproliferative disorders is unknown.
Bell et al 29 suggested that CD79a levels might provide a reliable distinction between CLL and MCL. In our laboratory, CD79a was tested on 39 classical CLL, nine atypical CLL and eight MCL fresh samples and no significant difference was found between atypical CLL and MCL. Therefore, in our experience, CD79a level was not helpful for the immunological differential diagnosis between these two last entities.
As suggested by Levy et al, 30 cyclin D1 expression allows the identification, among unclassified B cell chronic lymphoproliferative disorders, of a subset of aggressive disorders which represent a leukaemic counterpart of MCL. Cyclin D1 was not tested in this study but it would have to be in the future to look for its power in the differential diagnosis of CD5-positive B cell malignant proliferations.
Structural aberrations of chromosomal band 3q14 are frequent in B-CLL. Recently, it has been suggested that alterations of this particular region might also be of relevance for the pathogenesis of MCL. Rosenwald et al 31 wrote that the high rate of hemizygous deletions of this region in MCL, and especially a deletion pattern similar to B-CLL in some cases provide further evidence that a substantial proportion of MCL cases may share a common way of pathogenesis with B-CLL. Moreover, deletion in chromosome bands 11q22-q23, one of the most common chromosome aberrations in B-CLL, 32 has recently been shown to be common in mantle cell lymphoma, 33, 34 and inactivation of both alleles of the ATM gene
Figure 3
Dot plot of CD18 vs CD54 expression in a classical CLL, an atypical CLL and a MCL. A first gate is put around the lymphocyte population on a forward scatter (FSC)/side scatter (SSC) dot plot. To target the B lymphocyte subpopulation, a second gate is then put around the CD19-positive subpopulation on a CD19 vs SSC dot plot. The third plot shows the CD18 vs CD54 expression on the CD19-positive lymphocyte subpopulation.
was described in MCL 35 and in B-CLL. 32 It is not surprising therefore that the immunophenotype of MCL is so close to that of some CLL, especially the atypical ones. In the present work, atypical CLL was even found to be immunologically more close to MCL than to classical CLL.
In conclusion, the better understanding of the characteristics of malignant cells in chronic B cell leukaemias and NHL has resulted in various classification schemes. Nevertheless, even with optimal methods, there will always be some cases with atypical features that do not fit exactly into any of the proposed groups, perhaps reflecting the heterogeneity of the lymphoid system. In these cases, immunophenotyping could be helpful for the differential diagnosis.
